-+ 0.00%
-+ 0.00%
-+ 0.00%

Brookline Capital Downgrades Rein Therapeutics to Hold

Benzinga·01/21/2026 16:03:42
Listen to the news
Brookline Capital analyst Kemp Dolliver downgrades Rein Therapeutics (NASDAQ:RNTX) from Buy to Hold.